ThromboSLE
Accurate assessment of thrombosis risk in systemic lupus erythematosus
Total Cost €
0EC-Contrib. €
0Partnership
0Views
0ThromboSLE project word cloud
Explore the words cloud of the ThromboSLE project. It provides you a very rough idea of what is the project "ThromboSLE" about.
Project "ThromboSLE" data sheet
The following table provides information about the project.
| Coordinator |
GOOD BIOMARKER SCIENCES BV
Organization address contact info |
| Coordinator Country | Netherlands [NL] |
| Project website | http://gbsleiden.com/ |
| Total cost | 71˙429 € |
| EC max contribution | 50˙000 € (70%) |
| Programme |
1. H2020-EU.2.1.4. (INDUSTRIAL LEADERSHIP - Leadership in enabling and industrial technologies – Biotechnology) 2. H2020-EU.2.3.1. (Mainstreaming SME support, especially through a dedicated instrument) |
| Code Call | H2020-SMEINST-1-2016-2017 |
| Funding Scheme | SME-1 |
| Starting year | 2018 |
| Duration (year-month-day) | from 2018-03-01 to 2018-08-31 |
Partnership
Take a look of project's partnership.
| # | ||||
|---|---|---|---|---|
| 1 | GOOD BIOMARKER SCIENCES BV | NL (SASSENHEIM) | coordinator | 50˙000.00 |
Map
Project objective
Patients with systemic lupus erythematosus (SLE) are at high risk for thrombosis, a major and life-threatening complication of SLE and one of the main causes of death in SLE. There is a need for the accurate identification of patients that are at highest risk, as in this group the risk/benefit ratio for anticoagulant prophylaxis is advantageous. As in SLE thrombosis is caused by disease-specific mechanism, current testing methods fail to accurately assess thrombosis risk in SLE. Applying its unique expertise in functional analysis of blood plasma and cellular components, the Dutch SME Good Biomarker Sciences (GBS) has developed ThromboSLE, an innovative test to assess thrombosis risk in SLE with high sensitivity and specificity. Apart from reducing morbidity and mortality from thrombosis-related complications, the introduction of ThromboSLE will reduce healthcare costs: Thrombotic events cause high healthcare costs, including direct cost for interventions and rehabilitation cost and the total median costs for prophylaxis are four times lower than those for thrombotic event management. This opens a strong business opportunity for GBS, which aims to offer the test to hospitals treating and monitoring SLE patients in Europe and worldwide. The commercial exploitation of the diagnostic product will have substantial impact on GBS with respect to company growth and business strategy. With 160,000 SLE patients in the target market Western Europe, GBS forecasts to generate cumulated profits of €6.6 million from ThromboSLE sales by 2025. Before entering and investing into the innovation project (SMEi phase II) and to reach market readiness for ThromboSLE, GBS aims to conduct a feasibility study (SMEi phase I) for final verification of the technological as well as economic viability of the product.
Are you the coordinator (or a participant) of this project? Plaese send me more information about the "THROMBOSLE" project.
For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.
Send me an email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.
Thanks. And then put a link of this page into your project's website.
The information about "THROMBOSLE" are provided by the European Opendata Portal: CORDIS opendata.